Interestingly, NSCLCs carrying EGFR mutations have higher KDM1A expression than those carrying Kras mutations, suggesting that KDM1A inhibition may be more effective in NSCLC cells with EGFR mutations than in those with Kras mutations. Here, KRAS is linked to non-small cell lung carcinoma.